Document Detail

The endometrial effects of SERMs.
MedLine Citation:
PMID:  10874569     Owner:  NLM     Status:  MEDLINE    
The ideal selective oestrogen receptor modulator (SERM) would retain an oestrogen-like effect on the bones, the heart and cardiovascular apparatus, and the central nervous system, while acting as an anti-oestrogen on the breast and the genital tract. It seems, however, that such a compound is not available for clinical use yet. The uterine tissue, and particularly the endometrium, defines an area of special interest in the SERM action, since endometrial hyperplasia and cancer has been linked to agonistic oestrogen effects. Additionally, tamoxifen, the SERM which accumulates most of the clinical experience, has been associated with stimulatory effects on endometrium, including the development of cancer. In contrast, the more recent benzothiophenes, led by raloxifene, seem to operate as endometrial antagonists, thus providing an interesting alternative for clinical use. This review analyses the endometrial action of tamoxifen, including the information gathered from laboratory models, the observed endometrial effects in women using tamoxifen, and the epidemiological and molecular data which link the use of tamoxifen with endometrial cancer. A parallel examination of the raloxifene data presents the available experimental and clinical information, suggesting the endometrial neutrality of this compound.
A Cano; C Hermenegildo
Related Documents :
21550639 - Trends and co-trends of prostate-specific antigen and body mass index in a screened pop...
9264569 - Expression of nm23/nucleoside diphosphate kinase-a protein in endometrial carcinoma.
8714079 - Tamoxifen increases the proliferation of human endometrial stromal cells in in vitro. a...
11872959 - Pten expression in breast and endometrial cancer: correlations with steroid hormone rec...
6313179 - Immunohistochemical demonstration of relaxin in gynecologic tumors.
14501819 - Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, o...
25252859 - Significance of glioma-associated oncogene homolog 1 (gli1) expression in claudin-low b...
12559449 - Prognostic significance of the coexpression of p53 protein and c-erbb2 in breast cancer.
2658349 - The biology and natural history of breast cancer from the screening perspective.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Human reproduction update     Volume:  6     ISSN:  1355-4786     ISO Abbreviation:  Hum. Reprod. Update     Publication Date:    2000 May-Jun
Date Detail:
Created Date:  2000-10-12     Completed Date:  2000-10-12     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9507614     Medline TA:  Hum Reprod Update     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  244-54     Citation Subset:  IM    
Department of Pediatrics, Obstetrics and Gynecology, Facultad de Medicina, Valencia, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Breast Neoplasms / drug therapy
Endometrial Hyperplasia / chemically induced
Endometrial Neoplasms / chemically induced
Endometrium / drug effects*,  pathology
Estradiol / pharmacology
Polyps / chemically induced
Raloxifene / adverse effects,  pharmacology
Receptors, Estrogen / drug effects,  physiology
Selective Estrogen Receptor Modulators / adverse effects*,  pharmacology*
Tamoxifen / adverse effects,  pharmacology
Reg. No./Substance:
0/Receptors, Estrogen; 0/Selective Estrogen Receptor Modulators; 10540-29-1/Tamoxifen; 50-28-2/Estradiol; 84449-90-1/Raloxifene

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pure anti-oestrogens.
Next Document:  Skeletal effects of selective oestrogen receptor modulators (SERMs).